A Phase I/II Randomized, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Treatment Outcomes of Multidrug Treatment Including High Dose Rifampicin with or without Levofloxacin versus Standard Treatment for Pediatric Tuberculous Meningitis

Johns Hopkins University School of Medicine0 个研究点目标入组 27 人开始时间: 待定最近更新: 2024年4月1日

试验速览

暂无简介。

•1. Weight > 6kg
•2. Age greater than or equal to 6 months to less than or equal to 12 years and, in the opinion of the investigator, can tolerate the treatment and study participation.
•3. Probable or definite TBM according to diagnostic criteria (Appendix II) or a positive Gene Xpert CSF test.
•4.Since participants will all be under legal age of independent consent, a parent or legal guardian must be willing and able to provide informed consent. If the subject is of appropriate age, she/he will also be asked to give assent if developmentally appropriate and clinically possible.
•4. Participant can comply with the protocol requirements in the opinion of the site investigator.

•1. TB treatment for more than 7 days within 30 days prior to enrollment
•2. Exposure via close contact with someone with MDR-TB (or rifampicin mono-resistant TB) or personal history of MDR-TB (or rifampicin mono-resistant TB)
•3. Known intolerance or allergy to any of the study drugs
•4. Death imminent and expected within 24 hours, as assessed by the site investigator
•5. Moderate to severe renal or liver dysfunction (Grade 2 or higher abnormalities of creatinine, ALT, or direct bilirubin)
•6. HIV infection with any of the following:
•Planned initiation of antiretroviral treatment (ART) during the experimental treatment phase (first 8 weeks), as initiation of ART is contraindicated in that time period with TBM.
•On ART with planned continued use of a protease inhibitor or nevirapine (children can be switched to an acceptable alternative regimen and then participate)
•7.Having participated in other clinical studies with investigational agents or treatments within 8 weeks prior to enrollment.
•8.A clinically significant active medical condition or the presence of any concomitant severe illness or rapidly deteriorating health condition (outside of TB), which, in the opinion of the site investigator, would prevent appropriate participation in the trial, or that would make implementation of the protocol or interpretation of the study results difficult, or otherwise make the subject a poor candidate for a clinical trial.

发起方